Blog Post
Ossianix - Novo Nordisk Press Release
- by Krzysztof Wicher
- •
- 04 Sept, 2018
Ossianix and Novo Nordisk sign Research and Option Agreement on Blood Brain Barrier delivery technology for proteins in diabetes and other metabolic diseases
PHILADELPHIA,
PA, USA: Ossianix, Inc. today announced a research collaboration and
option agreement with Novo Nordisk to deliver therapeutic molecules in
diabetes and other metabolic diseases across the Blood Brain Barrier
(BBB) to the brain.
Under the terms of the agreement, Ossianix will use its patented single domain VNAR antibodies to deliver a predefined number of therapeutic agents of Novo Nordisk. Novo Nordisk will be responsible for the development and commercialization of the therapeutic products.
Under the terms of the agreement, Ossianix will use its patented single domain VNAR antibodies to deliver a predefined number of therapeutic agents of Novo Nordisk. Novo Nordisk will be responsible for the development and commercialization of the therapeutic products.
You can read the full press release here